nodes	percent_of_prediction	percent_of_DWPC	metapath
Tyloxapol—LPL—coronary artery disease	0.773	1	CbGaD
Tyloxapol—LPL—cardiac ventricle—coronary artery disease	0.00717	0.234	CbGeAlD
Tyloxapol—LPL—myocardium—coronary artery disease	0.00675	0.22	CbGeAlD
Tyloxapol—LPL—heart—coronary artery disease	0.00471	0.154	CbGeAlD
Tyloxapol—LPL—cardiovascular system—coronary artery disease	0.00444	0.145	CbGeAlD
Tyloxapol—LPL—cardiac atrium—coronary artery disease	0.00403	0.132	CbGeAlD
Tyloxapol—LPL—blood—coronary artery disease	0.00351	0.115	CbGeAlD
Tyloxapol—LPL—Disease—NPPA—coronary artery disease	7.07e-05	0.00036	CbGpPWpGaD
Tyloxapol—LPL—Disease—CYBB—coronary artery disease	7.07e-05	0.00036	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—GPX1—coronary artery disease	7.06e-05	0.000359	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—FZD2—coronary artery disease	7.03e-05	0.000358	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—UTS2R—coronary artery disease	7.03e-05	0.000358	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PLA2G2A—coronary artery disease	6.96e-05	0.000355	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—APOA2—coronary artery disease	6.96e-05	0.000355	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GPX2—coronary artery disease	6.96e-05	0.000355	CbGpPWpGaD
Tyloxapol—LPL—Disease—VCAN—coronary artery disease	6.9e-05	0.000351	CbGpPWpGaD
Tyloxapol—LPL—Disease—MAP2K3—coronary artery disease	6.9e-05	0.000351	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SFRP2—coronary artery disease	6.89e-05	0.000351	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—HK1—coronary artery disease	6.88e-05	0.00035	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GPX4—coronary artery disease	6.88e-05	0.00035	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—SULT1A1—coronary artery disease	6.88e-05	0.00035	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—ABCG5—coronary artery disease	6.88e-05	0.00035	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—CD36—coronary artery disease	6.87e-05	0.00035	CbGpPWpGaD
Tyloxapol—LPL—Disease—ALDOA—coronary artery disease	6.85e-05	0.000349	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—HADHA—coronary artery disease	6.8e-05	0.000346	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—LEP—coronary artery disease	6.79e-05	0.000346	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ADORA3—coronary artery disease	6.77e-05	0.000344	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—APOA4—coronary artery disease	6.77e-05	0.000344	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ADORA1—coronary artery disease	6.77e-05	0.000344	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GSTA1—coronary artery disease	6.72e-05	0.000342	CbGpPWpGaD
Tyloxapol—LPL—Disease—CST3—coronary artery disease	6.7e-05	0.000341	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—KDR—coronary artery disease	6.65e-05	0.000339	CbGpPWpGaD
Tyloxapol—LPL—Disease—DCN—coronary artery disease	6.65e-05	0.000339	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—LPA—coronary artery disease	6.64e-05	0.000338	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—MAPK14—coronary artery disease	6.61e-05	0.000336	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PGF—coronary artery disease	6.53e-05	0.000333	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PPBP—coronary artery disease	6.53e-05	0.000333	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PLCB3—coronary artery disease	6.43e-05	0.000328	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ITGA2B—coronary artery disease	6.43e-05	0.000327	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—DVL1—coronary artery disease	6.43e-05	0.000327	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—IL6ST—coronary artery disease	6.38e-05	0.000325	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—APOA5—coronary artery disease	6.37e-05	0.000324	CbGpPWpGaD
Tyloxapol—LPL—Disease—APOC3—coronary artery disease	6.26e-05	0.000319	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—P4HB—coronary artery disease	6.25e-05	0.000318	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CCL4—coronary artery disease	6.23e-05	0.000317	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—OPRD1—coronary artery disease	6.23e-05	0.000317	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GHR—coronary artery disease	6.23e-05	0.000317	CbGpPWpGaD
Tyloxapol—LPL—Disease—LDLR—coronary artery disease	6.23e-05	0.000317	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—AGT—coronary artery disease	6.19e-05	0.000315	CbGpPWpGaD
Tyloxapol—LPL—Disease—SLC9A1—coronary artery disease	6.15e-05	0.000313	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PLA2G1B—coronary artery disease	6.13e-05	0.000312	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—APOE—coronary artery disease	6.06e-05	0.000309	CbGpPWpGaD
Tyloxapol—LPL—Disease—SDC1—coronary artery disease	6.01e-05	0.000306	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—APOA1—coronary artery disease	5.99e-05	0.000305	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TLE4—coronary artery disease	5.98e-05	0.000304	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MEF2A—coronary artery disease	5.98e-05	0.000304	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—PPARG—coronary artery disease	5.91e-05	0.000301	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—GSK3B—coronary artery disease	5.88e-05	0.000299	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—CREB1—coronary artery disease	5.83e-05	0.000297	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—APOA2—coronary artery disease	5.82e-05	0.000297	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—VCAN—coronary artery disease	5.78e-05	0.000294	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—AVPR1A—coronary artery disease	5.75e-05	0.000293	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—ALDOA—coronary artery disease	5.74e-05	0.000292	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—IL6R—coronary artery disease	5.69e-05	0.00029	CbGpPWpGaD
Tyloxapol—LPL—Disease—PSMB5—coronary artery disease	5.68e-05	0.000289	CbGpPWpGaD
Tyloxapol—LPL—Disease—PSMA6—coronary artery disease	5.68e-05	0.000289	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—DCN—coronary artery disease	5.57e-05	0.000283	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—UTS2—coronary artery disease	5.56e-05	0.000283	CbGpPWpGaD
Tyloxapol—LPL—Disease—GOT2—coronary artery disease	5.5e-05	0.00028	CbGpPWpGaD
Tyloxapol—LPL—Disease—CYBA—coronary artery disease	5.47e-05	0.000279	CbGpPWpGaD
Tyloxapol—LPL—Disease—CALR—coronary artery disease	5.45e-05	0.000278	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—NR4A1—coronary artery disease	5.44e-05	0.000277	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—MMP2—coronary artery disease	5.43e-05	0.000276	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—ALDH2—coronary artery disease	5.42e-05	0.000276	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—P2RY12—coronary artery disease	5.38e-05	0.000274	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PLCB3—coronary artery disease	5.38e-05	0.000274	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HDAC9—coronary artery disease	5.38e-05	0.000274	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CX3CR1—coronary artery disease	5.33e-05	0.000271	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CASR—coronary artery disease	5.33e-05	0.000271	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PPARG—coronary artery disease	5.28e-05	0.000269	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP2C19—coronary artery disease	5.28e-05	0.000269	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—HBA1—coronary artery disease	5.28e-05	0.000269	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—LIPC—coronary artery disease	5.28e-05	0.000269	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PIK3C2A—coronary artery disease	5.28e-05	0.000269	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—APOC3—coronary artery disease	5.25e-05	0.000267	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GNA12—coronary artery disease	5.22e-05	0.000266	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—P4HB—coronary artery disease	5.22e-05	0.000266	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—BDKRB1—coronary artery disease	5.22e-05	0.000266	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CX3CL1—coronary artery disease	5.22e-05	0.000266	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—LDLR—coronary artery disease	5.21e-05	0.000265	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—POMC—coronary artery disease	5.21e-05	0.000265	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—FGF2—coronary artery disease	5.16e-05	0.000263	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GSTT1—coronary artery disease	5.15e-05	0.000262	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—SLC9A1—coronary artery disease	5.15e-05	0.000262	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PPP3R1—coronary artery disease	5.13e-05	0.000261	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CETP—coronary artery disease	5.09e-05	0.000259	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GCLC—coronary artery disease	5.09e-05	0.000259	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ADM—coronary artery disease	5.08e-05	0.000259	CbGpPWpGaD
Tyloxapol—LPL—Disease—HSPA1A—coronary artery disease	5.07e-05	0.000258	CbGpPWpGaD
Tyloxapol—LPL—Disease—JUNB—coronary artery disease	5.07e-05	0.000258	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—SDC1—coronary artery disease	5.04e-05	0.000256	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PDE4B—coronary artery disease	4.95e-05	0.000252	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CYBB—coronary artery disease	4.95e-05	0.000252	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—JAK2—coronary artery disease	4.94e-05	0.000252	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PSMA6—coronary artery disease	4.76e-05	0.000242	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PSMB5—coronary artery disease	4.76e-05	0.000242	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—ALB—coronary artery disease	4.75e-05	0.000242	CbGpPWpGaD
Tyloxapol—LPL—Disease—GOT1—coronary artery disease	4.75e-05	0.000242	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CTGF—coronary artery disease	4.65e-05	0.000237	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—HMGCR—coronary artery disease	4.61e-05	0.000234	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GOT2—coronary artery disease	4.61e-05	0.000234	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CCR3—coronary artery disease	4.53e-05	0.000231	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CRK—coronary artery disease	4.47e-05	0.000228	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SH2B3—coronary artery disease	4.41e-05	0.000225	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ATP2A2—coronary artery disease	4.41e-05	0.000225	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—VWF—coronary artery disease	4.41e-05	0.000225	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—APOC3—coronary artery disease	4.39e-05	0.000223	CbGpPWpGaD
Tyloxapol—LPL—Disease—PRKCE—coronary artery disease	4.38e-05	0.000223	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—LDLR—coronary artery disease	4.36e-05	0.000222	CbGpPWpGaD
Tyloxapol—LPL—Disease—TGFBR2—coronary artery disease	4.26e-05	0.000217	CbGpPWpGaD
Tyloxapol—LPL—Disease—KITLG—coronary artery disease	4.26e-05	0.000217	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CXCL2—coronary artery disease	4.26e-05	0.000217	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CCL3—coronary artery disease	4.26e-05	0.000217	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PLCB1—coronary artery disease	4.23e-05	0.000216	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SDC1—coronary artery disease	4.21e-05	0.000214	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—F2R—coronary artery disease	4.21e-05	0.000214	CbGpPWpGaD
Tyloxapol—LPL—Disease—STAT5A—coronary artery disease	4.17e-05	0.000212	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	4.15e-05	0.000212	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—FGB—coronary artery disease	4.12e-05	0.00021	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—ABCA1—coronary artery disease	4.1e-05	0.000209	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—MMP9—coronary artery disease	4.08e-05	0.000208	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—EDNRB—coronary artery disease	4.08e-05	0.000208	CbGpPWpGaD
Tyloxapol—LPL—Disease—APOB—coronary artery disease	4.03e-05	0.000205	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—THBS1—coronary artery disease	4.02e-05	0.000205	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PSMA6—coronary artery disease	3.98e-05	0.000203	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PSMB5—coronary artery disease	3.98e-05	0.000203	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GGT1—coronary artery disease	3.98e-05	0.000202	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GOT1—coronary artery disease	3.98e-05	0.000202	CbGpPWpGaD
Tyloxapol—LPL—Disease—FGF1—coronary artery disease	3.87e-05	0.000197	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—EDNRA—coronary artery disease	3.85e-05	0.000196	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CYBA—coronary artery disease	3.83e-05	0.000195	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ADRB1—coronary artery disease	3.83e-05	0.000195	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—DUSP6—coronary artery disease	3.82e-05	0.000194	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PLAT—coronary artery disease	3.75e-05	0.000191	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—VEGFA—coronary artery disease	3.66e-05	0.000187	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—BDKRB2—coronary artery disease	3.62e-05	0.000184	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CXCL12—coronary artery disease	3.62e-05	0.000184	CbGpPWpGaD
Tyloxapol—LPL—Disease—PPP2CA—coronary artery disease	3.61e-05	0.000184	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GSTP1—coronary artery disease	3.57e-05	0.000182	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—JUNB—coronary artery disease	3.55e-05	0.000181	CbGpPWpGaD
Tyloxapol—LPL—Disease—PRKCD—coronary artery disease	3.54e-05	0.00018	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PLCB1—coronary artery disease	3.54e-05	0.00018	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PPARGC1A—coronary artery disease	3.54e-05	0.00018	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—HMOX1—coronary artery disease	3.52e-05	0.000179	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CAT—coronary artery disease	3.47e-05	0.000177	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HTR7—coronary artery disease	3.47e-05	0.000177	CbGpPWpGaD
Tyloxapol—LPL—Disease—MTHFR—coronary artery disease	3.46e-05	0.000176	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—APOB—coronary artery disease	3.37e-05	0.000172	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—TGFB1—coronary artery disease	3.36e-05	0.000171	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ITGAV—coronary artery disease	3.3e-05	0.000168	CbGpPWpGaD
Tyloxapol—LPL—Disease—HIF1A—coronary artery disease	3.3e-05	0.000168	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—MAPK1—coronary artery disease	3.3e-05	0.000168	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—KNG1—coronary artery disease	3.29e-05	0.000168	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GSTM1—coronary artery disease	3.28e-05	0.000167	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—AGTR1—coronary artery disease	3.27e-05	0.000167	CbGpPWpGaD
Tyloxapol—LPL—Disease—APOE—coronary artery disease	3.22e-05	0.000164	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CXCL10—coronary artery disease	3.2e-05	0.000163	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PLG—coronary artery disease	3.19e-05	0.000162	CbGpPWpGaD
Tyloxapol—LPL—Disease—APOA1—coronary artery disease	3.19e-05	0.000162	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GPX1—coronary artery disease	3.14e-05	0.00016	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—TNF—coronary artery disease	3.14e-05	0.00016	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ADRB2—coronary artery disease	3.11e-05	0.000158	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PRKCE—coronary artery disease	3.07e-05	0.000156	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CD36—coronary artery disease	3.06e-05	0.000156	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SOCS1—coronary artery disease	3.06e-05	0.000156	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—S100B—coronary artery disease	3.05e-05	0.000155	CbGpPWpGaD
Tyloxapol—LPL—Disease—IL6ST—coronary artery disease	3.03e-05	0.000154	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PPP2CA—coronary artery disease	3.02e-05	0.000154	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SOCS3—coronary artery disease	3.02e-05	0.000154	CbGpPWpGaD
Tyloxapol—LPL—Disease—NOS2—coronary artery disease	3e-05	0.000153	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TGFBR2—coronary artery disease	2.99e-05	0.000152	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—KITLG—coronary artery disease	2.99e-05	0.000152	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—STAT5A—coronary artery disease	2.92e-05	0.000149	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MMP3—coronary artery disease	2.92e-05	0.000149	CbGpPWpGaD
Tyloxapol—LPL—Disease—KIT—coronary artery disease	2.91e-05	0.000148	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—MTHFR—coronary artery disease	2.9e-05	0.000148	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—APOB—coronary artery disease	2.82e-05	0.000144	CbGpPWpGaD
Tyloxapol—LPL—Disease—GSK3B—coronary artery disease	2.79e-05	0.000142	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—EDN1—coronary artery disease	2.78e-05	0.000141	CbGpPWpGaD
Tyloxapol—LPL—Disease—CREB1—coronary artery disease	2.77e-05	0.000141	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—AGT—coronary artery disease	2.76e-05	0.00014	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CCL5—coronary artery disease	2.75e-05	0.00014	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—FGF1—coronary artery disease	2.71e-05	0.000138	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CSF2—coronary artery disease	2.71e-05	0.000138	CbGpPWpGaD
Tyloxapol—LPL—Disease—IL6R—coronary artery disease	2.7e-05	0.000138	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—APOE—coronary artery disease	2.7e-05	0.000137	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—RPS6KB1—coronary artery disease	2.67e-05	0.000136	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MEF2C—coronary artery disease	2.67e-05	0.000136	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—APOA1—coronary artery disease	2.67e-05	0.000136	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ITGB3—coronary artery disease	2.6e-05	0.000132	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	2.56e-05	0.00013	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—IL6—coronary artery disease	2.53e-05	0.000129	CbGpPWpGaD
Tyloxapol—LPL—Disease—SERPINE1—coronary artery disease	2.53e-05	0.000129	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PPP2CA—coronary artery disease	2.53e-05	0.000129	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PRKCD—coronary artery disease	2.48e-05	0.000126	CbGpPWpGaD
Tyloxapol—LPL—Disease—FGF2—coronary artery disease	2.45e-05	0.000125	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HTR2A—coronary artery disease	2.43e-05	0.000124	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—C3—coronary artery disease	2.42e-05	0.000123	CbGpPWpGaD
Tyloxapol—LPL—Disease—NOS3—coronary artery disease	2.42e-05	0.000123	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PPARG—coronary artery disease	2.35e-05	0.00012	CbGpPWpGaD
Tyloxapol—LPL—Disease—JAK2—coronary artery disease	2.35e-05	0.00012	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—AKT1—coronary artery disease	2.34e-05	0.000119	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—POMC—coronary artery disease	2.32e-05	0.000118	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HIF1A—coronary artery disease	2.31e-05	0.000118	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—AGT—coronary artery disease	2.3e-05	0.000117	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—LEP—coronary artery disease	2.26e-05	0.000115	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—APOE—coronary artery disease	2.26e-05	0.000115	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—APOA1—coronary artery disease	2.23e-05	0.000114	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—KDR—coronary artery disease	2.21e-05	0.000113	CbGpPWpGaD
Tyloxapol—LPL—Disease—PTGS2—coronary artery disease	2.21e-05	0.000112	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MAPK14—coronary artery disease	2.2e-05	0.000112	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ESR1—coronary artery disease	2.16e-05	0.00011	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—F2—coronary artery disease	2.13e-05	0.000108	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—FN1—coronary artery disease	2.13e-05	0.000108	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IL6ST—coronary artery disease	2.12e-05	0.000108	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—ALB—coronary artery disease	2.11e-05	0.000108	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—NFKBIA—coronary artery disease	2.1e-05	0.000107	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—KIT—coronary artery disease	2.04e-05	0.000104	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—NOS3—coronary artery disease	2.02e-05	0.000103	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GSK3B—coronary artery disease	1.96e-05	9.95e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—POMC—coronary artery disease	1.94e-05	9.87e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CREB1—coronary artery disease	1.94e-05	9.87e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CCL2—coronary artery disease	1.9e-05	9.66e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IL6R—coronary artery disease	1.89e-05	9.63e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IGF1—coronary artery disease	1.87e-05	9.5e-05	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PTGS2—coronary artery disease	1.85e-05	9.42e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SERPINE1—coronary artery disease	1.77e-05	9.02e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—FGF2—coronary artery disease	1.71e-05	8.73e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—NOS3—coronary artery disease	1.69e-05	8.61e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—JAK2—coronary artery disease	1.64e-05	8.37e-05	CbGpPWpGaD
Tyloxapol—LPL—Disease—TGFB1—coronary artery disease	1.6e-05	8.13e-05	CbGpPWpGaD
Tyloxapol—LPL—Disease—MAPK1—coronary artery disease	1.57e-05	7.97e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CXCL8—coronary artery disease	1.5e-05	7.64e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CASP3—coronary artery disease	1.44e-05	7.31e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CCND1—coronary artery disease	1.4e-05	7.12e-05	CbGpPWpGaD
Tyloxapol—LPL—Disease—PIK3CA—coronary artery disease	1.36e-05	6.92e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MMP9—coronary artery disease	1.36e-05	6.91e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—VEGFA—coronary artery disease	1.22e-05	6.2e-05	CbGpPWpGaD
Tyloxapol—LPL—Disease—IL6—coronary artery disease	1.2e-05	6.13e-05	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PIK3CA—coronary artery disease	1.14e-05	5.8e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TGFB1—coronary artery disease	1.12e-05	5.69e-05	CbGpPWpGaD
Tyloxapol—LPL—Disease—AKT1—coronary artery disease	1.11e-05	5.65e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MAPK1—coronary artery disease	1.1e-05	5.58e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PIK3CA—coronary artery disease	9.52e-06	4.85e-05	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—AKT1—coronary artery disease	9.3e-06	4.73e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IL6—coronary artery disease	8.43e-06	4.29e-05	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—AKT1—coronary artery disease	7.77e-06	3.96e-05	CbGpPWpGaD
